Livagen
- Category
- Bioregulators
- Administration routes
- Injectable
- Regulatory status
- Not FDA-approved
A synthetic tetrapeptide marketed as a liver bioregulator that enters liver cells and acts on chromatin to support detox and repair. The case rests almost entirely on mechanism and animal data; claims of pain relief and digestive benefits are speculative, with essentially no human trials. No toxicology or pharmacokinetic data exist, and safety data trace mostly to one research group. Not an approved drug in the US; supply is unregulated research material.
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.
Overview
Livagen is a synthetic 4-amino-acid peptide (Lys-Glu-Asp-Ala) developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology in Russia. Classified as a liver bioregulator, it is unique among peptides because it works through epigenetic gene regulation — physically 'unpacking' tightly wound DNA in liver cells and aged immune cells to reactivate genes that become silenced with aging. It also inhibits enzymes that break down enkephalins (natural pain-relieving molecules) without directly activating opioid receptors.
How it works in the body
A tetrapeptide bioregulator (Lys-Glu-Asp-Ala) that targets liver cells. It penetrates hepatocyte membranes and interacts with chromatin to modulate gene expression involved in detoxification enzymes, protein synthesis, and the balance of inflammatory vs. protective signaling in liver tissue.
Research overview
Livagen research comes almost exclusively from Khavinson's group in St. Petersburg, with no independent replication by Western laboratories. The evidence consists of cell studies on immune cells from elderly donors (ages 75-88), animal models of liver disease, and enzyme inhibition assays. Key findings include: reactivation of age-silenced genes in elderly immune cells by physically unwinding compacted DNA, liver-protective and immune-boosting effects in animal models (with greatest benefit seen in older animals), potent inhibition of enkephalin-degrading enzymes, and restoration of digestive enzyme activity in old rats to near-youthful levels. No human clinical trials are registered on ClinicalTrials.gov. The lack of independent replication and absence of human trial data represent significant limitations — all claims should be considered preliminary until validated by research groups outside the originating laboratory.
Who researches Livagen?
Commonly researched by
People researching GI and digestive health
Studied for gastrointestinal protection, gut lining repair, or digestive support.
People researching longevity and anti-aging interventions
Studied for effects on aging pathways, cellular health, or lifespan extension.
People researching liver health
Studied for hepatoprotective effects or liver function support.
Important considerations for
Those who are pregnant or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Anyone under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Those with Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
Safety & interactions
General cautions
Pregnancy or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Children under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
How to read the ratings
- Benefits
- = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
- Risks
- = level of concern: High · Moderate · Low · Theoretical
- Interactions
- = direction with this peptide: Protective / Synergistic · Caution · Neutral
Risk summary(9)
Rated by level of concern
No formal toxicology studies meeting international regulatory standards (ICH guidelines) have been conducted.
HighPubMed search for 'Livagen' (19 records, none toxicological); no FDA approval record
Sustained chromatin decondensation could theoretically increase chromosomal instability or aneuploidy risk — this has not been investigated.
TheoreticalPMID 17460203; PMID 18830022 (context only); PMID 25541832 (context only)
No pharmacokinetic data exist (absorption, distribution, metabolism, elimination are all unknown in humans).
ModeratePubMed search for 'Livagen' — no pharmacokinetic records
No reproductive or developmental toxicity assessments have been performed.
ModeratePubMed search for 'Livagen' — no reproductive toxicology records
All safety data originate exclusively from the Khavinson research network with no independent Western verification.
HighPubMed author/journal distribution across all 19 Livagen records
Human oral bioavailability is unknown; laboratory findings suggest resistance to intestinal peptide hydrolysis.
ModeratePMID 16075683
No drug interaction studies have been conducted.
ModeratePubMed search for 'Livagen' — no interaction or CYP records
Long-term effects of repeated administration are unknown.
ModeratePubMed search for 'Livagen' — no chronic-administration records
Commercial products may vary in purity and composition; no standardized pharmaceutical quality controls apply.
HighNo FDA approval or USP monograph for Livagen/KEDA
Interaction summary(8)
Rated by direction with this peptide
Active malignancy or concurrent cytotoxic chemotherapy
CautionTheoreticalLivagen's defining action is deheterochromatinization and reactivation of ribosomal genes in human cells (PMID 17460203; PMID 12533768) — de-repressing chromatin and raising ribosome biogenesis is a direction of effect that warrants caution in proliferative disease. The same network has applied peptide bioregulators to genomic parameters in ductal breast cancer patients (PMID 28574395), but that is an exploratory cytogenetic study, not an oncology safety study; no oncology safety or chemotherapy co-administration data exist in any species.
PMID 17460203; PMID 12533768; PMID 28574395
Drugs cleared by hepatic CYP450 metabolism (e.g. warfarin, statins, immunosuppressants, antiepileptics)
CautionTheoreticalThe peptide is reported to alter hepatocyte gene expression and protein-synthesis rhythm (PMID 15926314), so a shift in clearance of narrow-therapeutic-index drugs is conceivable in principle. No effect of Livagen on any CYP isoform or drug transporter has ever been measured, and no specific enzyme-induction or -inhibition claim is supported by the literature.
PMID 15926314; no published CYP data
Opioid analgesics and other opioidergic agents
SynergisticTheoreticalLivagen inhibited enkephalin-degrading enzymes in human serum in vitro, more efficiently than Epitalon in the same assay (PMID 12942748), so an additive endogenous-opioid effect is conceivable. No in vivo enkephalin measurement, analgesia model, or opioid co-administration study exists in animals or humans.
PMID 12942748
Hepatotoxic drugs (acetaminophen, methotrexate, isoniazid, amiodarone)
ProtectiveTheoreticalKEDA is reported to show hepatoprotective activity in experimental liver-pathology models and to support regeneration in organotypic liver culture (PMID 32362099; PMID 12577697). This is rodent/ex vivo evidence from a single research network with no human data, and must not be treated as license to exceed hepatotoxic drug limits or to skip liver-enzyme monitoring.
PMID 32362099; PMID 12577697
Immunosuppressants (corticosteroids, calcineurin inhibitors, biologics)
CautionTheoreticalA Russian-language review attributes immunoprotective as well as hepatoprotective properties to KEDA (PMID 32362099), so opposition to intentional immunosuppression is mechanistically conceivable. The immunoprotective claim is a review-level assertion rather than a controlled immunological experiment, and no co-administration data exist in animals or humans.
PMID 32362099
Other Khavinson short peptide bioregulators (Epitalon/AEDG, Vilon/KE)
CautionTheoreticalThese peptides were studied side by side and produced overlapping chromatin-decondensation and enkephalinase-inhibition effects (PMID 15085253; PMID 12942748). Taking them together therefore plausibly adds to the same unmeasured epigenetic action rather than providing independent benefit — treated as a caution, not a synergy, because the combined effect is unquantified and unstudied in combination.
PMID 15085253; PMID 12942748
Alcohol and chronic ethanol exposure
NeutralTheoreticalNo ethanol-specific study of Livagen exists in any species. General hepatoprotection in experimental liver-pathology models and stimulation of hepatocyte protein synthesis (PMID 32362099; PMID 15926314) have been extrapolated to alcohol elsewhere, but that extrapolation is unsupported; no protective effect against ethanol should be assumed, and Livagen must not be treated as offsetting alcohol-related liver injury.
PMID 32362099; PMID 15926314 (no ethanol-specific data)
Routine clinical laboratory monitoring (liver function panels, CBC)
NeutralTheoreticalNo assay interference has been reported, and none is expected for a tetrapeptide. Given the total absence of human safety data, baseline and periodic LFTs and CBC are the only practical way to detect a problem.
No published assay-interference reports
Known risks(9)
No formal toxicology studies meeting international regulatory standards (ICH guidelines) have been conducted.
Sustained chromatin decondensation could theoretically increase chromosomal instability or aneuploidy risk — this has not been investigated.
No pharmacokinetic data exist (absorption, distribution, metabolism, elimination are all unknown in humans).
No reproductive or developmental toxicity assessments have been performed.
All safety data originate exclusively from the Khavinson research network with no independent Western verification.
Human oral bioavailability is unknown; the cited rat study reported weak hydrolysis and resistance to small-intestinal peptide hydrolases.
No drug interaction studies have been conducted.
Long-term effects of repeated administration are unknown.
Commercial products may vary in purity and composition; no standardized pharmaceutical quality controls apply.
Drug interactions(5)
No formal drug interaction studies have been conducted for Livagen.
No interaction data available
Theoretical concern: As an inhibitor of enkephalin-degrading enzymes, Livagen could theoretically potentiate endogenous opioid peptide effects, though no opioid receptor binding was observed in vitro.
No interaction data available
Theoretical concern: Patients on hepatically metabolized medications should exercise caution given Livagen's hepatic bioregulatory activity, though specific interactions are unstudied.
No interaction data available
Theoretical concern: Concurrent use with other chromatin-modifying agents (e.g., HDAC inhibitors, DNA methyltransferase inhibitors) could have additive or unpredictable epigenetic effects.
No interaction data available
Theoretical concern: Concurrent use with other Khavinson peptides (Epithalon, Vilon, Ovagen) may have additive chromatin effects — no combination studies exist.
No interaction data available
Research & benefits
Evidence base
- Evidence Level
- Preclinical only
- Total Studies
- 8
- Human Studies
- 0
All evidence comes from in vitro human cell studies and animal models. No controlled human clinical trials have been conducted or registered. Research originates almost exclusively from Khavinson's group in Russia and Georgia, with no independent Western replication.
Researched for(4)
Rated by confidence in the evidence
Chromatin remodeling and epigenetic rejuvenation
LowConsistent in cultured blood cells from older donors, but never tested in living people.
PMID 12533768; PMID 15085253; PMID 17460203; PMID 16705247
Hepatoprotection and liver function restoration
SpeculativeBased on animal and cell studies only; no human liver trials exist for this peptide.
PMID 12577697; PMID 15926314; PMID 32362099; ClinicalTrials.gov (0 records for Livagen)
Enkephalin preservation (endogenous pain modulation support)
SpeculativeSingle lab test showed enzyme inhibition in serum; no pain or mood studies done.
PMID 12942748
Age-dependent normalization of digestive enzyme activity
SpeculativeFrom a single rat study only; no human digestive or clinical data available.
PMID 16075683
Benefits(4)
Chromatin remodeling and epigenetic rejuvenation
In vitro studies on lymphocytes from elderly humans (ages 75-88) showed decondensation of pericentromeric and telomeric heterochromatin, reactivation of ribosomal genes, and release of age-repressed genes (Khavinson et al., 2002; Lezhava et al., 2007).
Hepatoprotection and liver function restoration
Animal models of liver fibrosis, acute hepatitis, and chronic hepatitis demonstrated restoration of liver function, normalized immune and antioxidant status, with maximum hepatoprotective effects in aging animals (Kuznik et al., 2020).
Enkephalin preservation (endogenous pain modulation support)
In vitro enzyme assays showed Livagen inhibits enkephalin-degrading enzymes from human serum more potently than puromycin and leupeptin (IC50 ~20 µM), without binding mu- or delta-opioid receptors (Kost et al., 2003).
Age-dependent normalization of digestive enzyme activity
Two-week oral administration in rats showed enzyme activity normalization in old animals to levels approaching young controls, with tissue-specific and age-dependent effects (Timofeeva et al., 2005).
Key studies(7)
Effects of Livagen peptide on chromatin activation in lymphocytes from old people
In vitro (human lymphocytes)Lymphocyte cultures from elderly donors (ages 75-88)Acute exposureKhavinson VKh, Lezhava TA, Monaselidze JG, Dzhokhadze TA, Dvalishvili NA, Bablishvili NK, Ryadnova IYu
Bulletin of Experimental Biology and Medicine
2002
Livagen caused de-heterochromatinization of chromatin, activating ribosomal genes, inducing decondensation of pericentromeric structural heterochromatin, and releasing genes repressed due to age-related chromatin condensation.
The influence of polypeptide liver complex and tetrapeptide KEDA on organism physiological function in norm and age-related pathology
Review of animal and in vitro researchMultiple experimental modelsVariedKuznik BI, Khasanova NB, Ryzhak GA, Mezsheriakova IE, Khavinson VK
Advances in Gerontology
2020
Both the liver polypeptide complex (Ventvil) and KEDA tetrapeptide demonstrated high efficacy in restoring liver function in models of fibrosis, acute hepatitis, and chronic hepatitis, normalizing immune and antioxidant status with maximum hepato- and immunoprotective effects observed in aging animals.
Effect of new peptide bioregulators livagen and epitalon on enkephalin-degrading enzymes in human serum
In vitro (human serum enzymes)Enzyme assays with human serumAcute exposureKost NV, Sokolov OYu, Gabaeva MV, Zolotarev YuA, Malinin VV, Khavinson VKh
Izvestiia Akademii Nauk. Seriia Biologicheskaia
2003
Livagen inhibited enkephalin-degrading enzymes from human serum with IC50 of 20 µM, proving more efficient than known peptidase inhibitors (puromycin, leupeptin). No interaction with mu- or delta-opioid receptors was observed.
Effect of peptide Livagen on activity of digestive enzymes in gastrointestinal tract and non-digestive organs in rats of different ages
Animal study (rats)Rats of different agesTwo-week oral administrationTimofeeva NM, Khavinson VKh, Malinin VV, Nikitina AA, Egorova VV
Advances in Gerontology
2005
Livagen produced age-dependent effects on digestive enzyme activity: decreasing activity in young rats while increasing it in old rats, with enzyme levels in old animals approaching those of young controls after treatment.
Tissue-specific action of peptides in tissue culture of rats of various ages
In vitro (rat tissue cultures)Organ-typical cultures from rats of various agesAcute exposureKhavinson VKh, Malinin VV, Chalisova NI, Grigor'ev EI
Advances in Gerontology
2002
Livagen and other synthetic peptide bioregulators exerted tissue-specific effects in organ-typical cultures, with selective actions depending on tissue type across different ages.
Activation of pericentromeric and telomeric heterochromatin in cultured lymphocytes from old individuals
In vitro (human lymphocytes)Lymphocyte cultures from elderly donorsAcute exposureLezhava T, Jokhadze T
Annals of the New York Academy of Sciences
2007
Livagen and cobalt ions induced deheterochromatinization of both pericentromeric and telomeric heterochromatin regions in lymphocytes from elderly individuals.
Epigenetic modification under the influence of peptide bioregulators on the 'old' chromatin
In vitro study of human lymphocyte culturesLymphocyte cultures from donors aged 75–88Lezhava T, Jokhadze T, Monaselidze J, et al.
Georgian Medical News
2023
Cell-culture study reporting selective chromatin changes after exposure to several peptide bioregulators, including Livagen; clinical benefit was not tested.
Regulation & availability
Why researchers look at it
In vitro studies on immune cells from elderly donors (ages 75-88) showed this tetrapeptide physically unpacked compacted DNA and reactivated genes silenced by aging — suggesting a direct epigenetic rejuvenation mechanism. However, all ~8 published studies originate from a single Russian laboratory group, with zero registered human clinical trials and no independent Western replication. Until these epigenetic reprogramming claims are validated by outside research groups, Livagen remains one of the most speculative entries in peptide research.
- Estimated cost
- $30-80/mo oral capsules
- FDA status
- Not FDA-approved. No Investigational New Drug (IND) application filed. Not listed in any FDA drug database. No clinical trials registered on ClinicalTrials.gov. The peptide lacks an ATC (Anatomical Therapeutic Chemical) code and has no CAS registry number. Not approved by the EMA or any other major Western regulatory body.
- WADA status
- Livagen is not specifically named on the 2026 WADA Prohibited List. S0 prohibits pharmacological substances without governmental approval for human therapeutic use when no subsequent section applies, regardless of demonstrated performance enhancement. Livagen's product-specific status requires anti-doping confirmation.
- Prescribability
- No — Livagen is not approved by any major Western regulatory agency (FDA, EMA) and is not a licensed pharmaceutical.
- Availability
- Livagen is not approved as a pharmaceutical in any major Western jurisdiction. It has a history of clinical use in some Eastern European settings where Khavinson peptide bioregulators are used, and it appears in dietary supplement markets in some jurisdictions with less stringent regulation. The liver polypeptide complex Ventvil (containing KEDA among other peptides) has been used clinically in Russia, but the synthetic KEDA tetrapeptide itself lacks separate pharmaceutical registration.
International status
EU
Not approved
US
Not approved
Russia
Used clinically (Khavinson bioregulator protocol)
Worldwide
Limited to Russian clinical use
Regulatory timeline(8)
- Late 1990sLivagen (KEDA tetrapeptide) developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology as part of the bioregulatory peptide research program.
- 2002First published studies on Livagen's chromatin activation effects in elderly lymphocytes and tissue-specific action in rat organ cultures.
- 2003Publication of enkephalin-degrading enzyme inhibition study demonstrating Livagen's IC50 of 20 µM.
- 2005Publication of digestive enzyme normalization study in rats of different ages.
- 2007Study on pericentromeric and telomeric heterochromatin activation in elderly lymphocytes.
- 2020Comprehensive review of KEDA tetrapeptide and liver polypeptide complex (Ventvil) in age-related pathology models.
- 2023Most recent publication reviewing epigenetic modification of aged chromatin by peptide bioregulators including Livagen.
- PresentNo clinical trials registered. No FDA/EMA approval process initiated.
Sources & FAQs
Research sources(8)
- PubMed — Khavinson et al. 2002 (Chromatin activation)
- PubMed — Kuznik et al. 2020 (Liver complex and KEDA)
- PubMed — Kost et al. 2003 (Enkephalin-degrading enzymes)
- PubMed — Timofeeva et al. 2005 (Digestive enzymes)
- PubMed — Khavinson et al. 2002 (Tissue-specific action)
- PubMed — Lezhava et al. 2007 (Telomeric heterochromatin)
- PubMed — Lezhava et al. 2023 (Epigenetic modification review)
- Wikipedia — Livagen
Frequently asked questions(5)
What is Livagen and how does it work?
Livagen is a synthetic four-amino-acid peptide (Lys-Glu-Asp-Ala) developed by Russian scientist Vladimir Khavinson as a liver bioregulator. It works by loosening tightly packed DNA (chromatin) in aging cells, potentially reactivating genes that become silenced with age. It also protects natural pain-modulating molecules (enkephalins) from being broken down.
Is there strong clinical evidence for Livagen?
No. All evidence comes from laboratory cell studies and animal experiments, almost exclusively from Khavinson's research group. No controlled human clinical trials have been conducted. The research has not been independently replicated by Western laboratories.
Is Livagen safe?
No significant toxicity has been reported in the limited studies available, and no cytotoxic effects were observed in cell cultures. However, formal toxicology studies meeting international standards have not been conducted. There are no pharmacokinetic data, no reproductive toxicity assessments, and no long-term safety studies. The theoretical risk of sustained chromatin decondensation on genomic stability has not been explored.
Can I take Livagen orally?
One rat study reported weak digestive hydrolysis and biological effects after oral administration. Human oral bioavailability and any delivery advantage of injection remain unestablished.
How does Livagen compare to other Khavinson peptides like Epithalon?
Epithalon (AEDG) targets the pineal gland and has a somewhat larger research base, including some human observational data. Livagen (KEDA) specifically targets the liver and chromatin remodeling. Both share the ability to induce chromatin decondensation but in different tissue contexts. Neither has undergone rigorous controlled clinical trials.